Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening

By LabMedica International staff writers
Posted on 22 Jan 2025

Tuberculosis (TB) continues to be a leading cause of global mortality, with 10. More...

6 million new cases and 1.6 million deaths annually. Diagnosing TB remains difficult, with smear microscopy offering only moderate sensitivity and specificity, and culture methods having slow sample-to-answer times. Though newer tests like Elispot, Elisa Blood assays, and PCR assays have shown promise, they have not significantly impacted global TB detection due to their limitations. Now, a breakthrough has been made with the first qualitative real-time polymerase chain reaction (PCR) assay that integrates Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology to detect Mycobacterium tuberculosis (Mtb) cell-free DNA (cfDNA) in human serum and EDTA plasma.

IntelliGenome (Houston, TX, USA) has developed the first molecular diagnostic platform capable of detecting low-abundance target nucleic acids in blood. This platform enables precise detection of disease-specific cell-free DNA (cfDNA), making it ideal for early diagnosis and mass screening. The CRISPR-TB Blood test by IntelliGenome provides a rapid, accurate, and cost-effective way to diagnose both pulmonary tuberculosis (PTB) and extra-pulmonary tuberculosis (EPTB) in all patient groups. The test identifies species-specific TB cfDNA sequences directly from blood samples, eliminating the need for sputum collection, which is especially beneficial for vulnerable populations such as children, elderly patients, and the critically ill. IntelliGenome’s CRISPR-TB Blood Test has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

"The FDA's Breakthrough Device Designation for our CRISPR-TB Blood Test is a significant milestone for IntelliGenome," said Wilson Zhang MD MSc, CEO of IntelliGenome. “This recognition highlights our commitment to advancing innovative, accessible solutions for tuberculosis diagnosis and improving patient outcomes.”

Related Links:
IntelliGenome


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
PlGF Test
Quidel Triage PlGF Test
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.